Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trialsAlexa B. Kimball, Elisa Muscianisi, A. Villani et al.|The Lancet|2023Cited by 318
Assessing Long-Term Pain Reduction with Secukinumab in Moderate to Severe Hidradenitis Suppurativa: A Post Hoc Analysis of the SUNSHINE and SUNRISE Phase 3 TrialsJohn R Ingram, Alexa B. Kimball, Jacek C. Szepietowski et al.|Dermatology and Therapy|2025Cited by 2
64857 The impact of continuous secukinumab treatment through week 104 on efficacy outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trialsAlexa B. Kimball, Jacek C. Szepietowski, D. Ioannides et al.|Journal of the American Academy of Dermatology|2025Cited by 0
64674 The impact of continuous secukinumab treatment through week 104 on patient reported outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trialsAlexa B. Kimball, Jacek C. Szepietowski, D. Ioannides et al.|Journal of the American Academy of Dermatology|2025Cited by 0